<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940919-2-00067</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Advisory Committees; Notice of Meetings</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=10 g=1 f=2 --> MEETINGS:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The following advisory committee meetings are announced: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee) <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . October 4, 1994, 9 a.m., Hubert H. Humphrey Bldg., Stonehenge Room, suite 615&hyph;F, 200 Independence Ave. SW., Washington, DC. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open committee discussion, 9 a.m. to 1:30 p.m.; open public hearing, 1:30 p.m. to 2:30 p.m., unless public participation does not last that long; open committee discussion, 2:30 p.m. to 4 p.m.; Ronald F. Coene, National Center for Toxicological Research (HFT&hyph;10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;3155. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee shall advise the Secretary and the Assistant Secretary for Health concerning its oversight of the conduct of the Ranch Hand Study by the Air Force and other studies in which the Secretary or the Assistant Secretary for Health believes involvement by the advisory committee is desirable. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before September 23, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee will initiate the review of the report analyzing the 1992 health examination of participants in the Air Force Health study entitled ``An Epidemiologic Investigation of Health Effects in Air Force Personnel Following Exposure to Herbicides.'' This review will include the chapters dealing with General Health, Dermatology, Renal Function, and Pulmonary Function. Criteria for release of data sets from previous health examinations conducted for the Air Force Health study will also be discussed. Representatives from the Department of Veterans Affairs will present an outline of their plan for conduct of a health study of Army veterans assigned to Chemical Corps units in Vietnam. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Dental Drug Products Panel Plaque Subcommittee (Nonprescription Drugs) of the Medical Devices Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . October 11 and 12, 1994, 9 a.m., Holiday Inn_Silver Spring, International Ballroom, 8777 Georgia Ave., Silver Spring, MD. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open committee discussion, October 11, 1994, 9 a.m. to 12 m.; open public hearing, 12 m. to 3 p.m., unless public participation does not last that long; open committee discussion, 3 p.m. to 5 p.m.; open committee discussion, October 12, 1994, 9 a.m. to 11 a.m.; open public hearing, 11 a.m. to 12 m., unless public participation does not last that long; open committee discussion, 12 m. to 4 p.m.; Jeanne L. Rippere or Stephanie A. Mason, Center for Drug Evaluation and Research (HFD&hyph;813), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1003. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation. <!-- PJG 0012 frnewline --> The Dental Products Panel of the Medical Devices Advisory Committee functions at times as a nonprescription drug advisory panel. As such, the panel reviews and evaluates available data concerning the safety and effectiveness of active ingredients, and combinations thereof, of various currently marketed nonprescription drug products for human use, the adequacy of their labeling, and advises the Commissioner of Food and Drugs on the promulgation of monographs establishing conditions under which these drugs are generally recognized as safe and effective and not misbranded. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on the general issues pending before the subcommittee. Those desiring to make formal presentations should notify the contact person before September 30, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The subcommittee will continue with its discussions held during the June 28 and 29, 1994, meeting as follows: (1) The possible relationship of alcohol-containing mouthwashes to the development of oral and pharyngeal cancers, and (2) work on developing general guidelines for determining the safety and effectiveness of antiplaque and antiplaque-related drug products. The subcommittee will also work on a draft document to be presented to the Dental Products Panel at a future meeting. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Dental Device Ingredient Labeling Subcommittee of the Dental Products Panel of the Medical Devices Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . October 12, 1994, 9 a.m., Gaithersburg Hilton Hotel, Salon C, 620 Perry Pkwy., Gaithersburg, MD. A limited number of overnight accommodations have been reserved at the Gaithersburg Hilton Hotel. Attendees requiring overnight accommodations may contact the hotel at 301&hyph;977&hyph;8900 and reference the FDA Panel meeting block. Reservations will be confirmed at the group rate based on availability. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open public hearing, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 5 p.m.; Carolyn A. Tylenda, Center for Devices and Radiological Health (HFZ&hyph;410), Food and Drug Administration, 1390 Piccard Dr., Rockville, MD, 301&hyph;594&hyph;3090.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before October 1, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee will discuss dental device ingredient labeling. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Cardiovascular and Renal Drugs Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . October 13 and 14, 1994, 9 a.m., National Institutes of Health, Clinical Center, Bldg. 10, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, MD. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open public hearing, October 13, 1994, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 5 p.m.; open committee discussion, October 14, 1994, 9 a.m. to 5 p.m.; Joan C. Standaert, Center for Drug Evaluation and Research (HFD&hyph;110), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 419&hyph;259&hyph;6211 or Valerie M. Mealy, Advisors and Consultants Staff, 301&hyph;443&hyph;4695. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in cardiovascular and renal disorders. <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before October 1, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . On October 13, 1994, the committee will discuss drug interactions and antianginal guidelines. On October 14, 1994, the committee will discuss the new drug application (NDA) 20&hyph;377 for Cordarone <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , I.V. amiodarone HCl, Wyeth-Ayerst Laboratories, to be indicated for life-threatening arrhythmias. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Dental Products Panel of the Medical Devices Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . October 13 and 14, 1994, 9 a.m., Gaithersburg Hilton Hotel, Salon C, 620 Perry Pkwy., Gaithersburg, MD. A limited number of overnight accommodations have been reserved at the Gaithersburg Hilton Hotel. Attendees requiring overnight accommodations may contact the hotel at 301&hyph;977&hyph;8900 and reference the FDA Panel meeting block. Reservations will be confirmed at the group rate based on availability. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open public hearing, October 13, 1994, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 5 p.m.; open public hearing, October 14, 1994, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 3 p.m., Carolyn A. Tylenda, Center for Devices and Radiological Health (HFZ&hyph;410), Food and Drug Administration, 1390 Piccard Dr., Rockville, MD, 301&hyph;594&hyph;3090. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before October 1, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . On October 13 and 14, 1994, the committee will discuss: (1) Classification of muscle monitor devices; (2) reclassification of dental mercury; (3) bone filling and augmentation materials; (4) dental device ingredient labeling; and (5) draft guidance documents for dental endosseous implants and temporomandibular joint implants. Copies of the draft guidance documents are available from the Division of Small Manufacturers Assistance, Center for Devices and Radiological Health (HFZ&hyph;220), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 800&hyph;638&hyph;2041 or 301&hyph;443&hyph;6597. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Blood Products Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . October 20 and 21, 1994, 8 a.m., Holiday Inn_Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open committee discussion, October 20, 1994, 8 a.m. to 9:20 a.m.; open public hearing, 9:20 a.m. to 9:40 a.m., unless public participation does not last that long; open committee discussion, 9:40 a.m. to 11:40 a.m.; open public hearing, 11:40 a.m. to 12 m., unless public participation does not last that long; open committee discussion, 12 m. to 2:30 p.m.; open public hearing, 2:30 p.m. to 3 p.m., unless public participation does not last that long; open committee discussion, 3 p.m. to 5 p.m.; open committee discussion, October 21, 1994, 8 a.m. to 9:30 a.m.; open public hearing, 9:30 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 12:30 p.m.; Linda A. Smallwood, Office of Blood Research and Review (HFM&hyph;300), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301&hyph;594&hyph;6700. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee reviews and evaluates data on the safety and effectiveness, and appropriate use of blood products intended for use in the diagnosis, prevention, or treatment of human diseases. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before  <!-- PJG 0012 frnewline --> October 10, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . On October 20, 1994, the committee will discuss and provide recommendations for: (1) Revised donor testing and suitability criteria related to the use of treponemal screening tests for syphilis, (2) issues related to the dating period for irradiated red blood cells, and (3) issues concerning donor suitability. On October 21, 1994, the committee will discuss public health issues related to the use of gloves by phlebotomists in blood establishments.  <!-- PJG 0012 frnewline -->   <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . October 21, 1994, 10 a.m., Holiday Inn_Gaithersburg, Walker and Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD. A limited number of overnight accommodations have been reserved at the Holiday Inn_Gaithersburg. Attendees requiring overnight accommodations may contact the hotel at 301&hyph;948&hyph;8900 and reference the FDA Panel meeting block. Reservations will be confirmed at the group rate based on availability. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open public hearing, 10 a.m. to 11 a.m., unless public participation does not last that long; open committee discussion, 11 a.m. to 4 p.m., Djuana Blagmon, Center for Devices and Radiological Health (HFZ&hyph;440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301&hyph;594&hyph;2096. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the committee <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before October 14, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.  <!-- PJG 0012 frnewline -->   <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The committee will discuss the classification of immunohistochemical devices. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> Science Board to the Food and Drug Administration <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . October 21, 1994, 8:30 a.m., Bethesda Ramada Hotel and Conference Center, Ambassador Ballrooms I and II, 8400 Wisconsin Ave., Bethesda, MD. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open committee discussion, 8:30 a.m. to 2:30 p.m.; open public hearing, 2:30 p.m. to 3:30 p.m., unless public participation does not last that long; open committee discussion, 3:30 p.m. to 6 p.m.; Neil L. Wilcox, Office of the Senior Advisor for Science (HF&hyph;33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;5839. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the board <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The board shall provide advice primarily to the agency's Senior Science Advisor and, as needed, to the Commissioner and other appropriate officials on specific complex and technical issues as well as emerging issues within the scientific community in industry and academia. Additionally, the board will provide advice to the agency on keeping pace with technical and scientific evolutions in the fields of regulatory science; on formulating an appropriate research agenda; and on upgrading its scientific and research facilities to keep pace with these changes. It will also provide the means for critical review of agency sponsored intramural and extramural scientific research programs. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the board. Those desiring to make formal presentations must notify the contact person before October 7, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants. Each presenter will be limited in time and not all requests to speak may be able to be accommodated. All written statements submitted in a timely fashion will be provided to the board. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open committee discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The board will continue to discuss issues related to the test strategy for toxicity and carcinogenicity of substances regulated by FDA. The primary agenda item will consist of short presentations followed by general discussion on the development and validation of alternatives to the 2-year rodent carcinogenicity assay. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 --> National Task Force on AIDS Drug Development <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Date, time, and place <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . October 27, 1994, 9:30 a.m., October 28, 1994, 8:30 a.m., The Hyatt Regency_Crystal City, Regency Rooms C and D, 2799 Jefferson Davis Hwy., Arlington, VA. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Type of meeting and contact person <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Open task force discussion, October 27, 1994, 9:30 a.m. to 4:30 p.m.; open public hearing, 4:30 p.m. to 5:30 p.m., unless public participation does not last that long; open task force discussion, October 28, 1994, 8:30 a.m. to 11:30 a.m.; Jean H. McKay or Kimberley M. Miles, Office of AIDS and Special Health Issues (HF&hyph;12), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;0104.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> General function of the task force <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The Task Force on AIDS Drug Development shall identify any barriers and provide creative options for the rapid development and evaluation of treatments for human immunodeficiency virus (HIV) infection and its sequelae. It also advises on issues related to such barriers, and provides options for the elimination of these barriers.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Open task force discussion <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The task force will present, hear, and discuss issues on the barriers to acquired immune deficiency syndrome (AIDS) drug development from the perspective of task force members, members of the Federal government, and the public. The task force will determine how to proceed with overcoming the barriers to AIDS drug development. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Agenda_Open public hearing <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Interested persons may present data, information, or views, orally or in writing, on issues pending before the task force. Those desiring to make formal presentations should notify the contact person before October 19, 1994, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above. <!-- PJG 0012 frnewline --> The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work. <!-- PJG 0012 frnewline --> Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants. <!-- PJG 0012 frnewline --> Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting. <!-- PJG 0012 frnewline --> Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion. <!-- PJG 0012 frnewline --> The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting. <!-- PJG 0012 frnewline --> Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI&hyph;35), Food and Drug Administration, rm. 12A&hyph;16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.  <!-- PJG 0012 frnewline --> This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: September 13, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUMMARY> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Linda A. Suydam, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Interim Deputy Commissioner for Operations. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;23151 Filed 9&hyph;16&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            